Virtual Library

Start Your Search

David Koenig

Author of

  • +

    P2.12 - Small Cell Lung Cancer/NET (ID 180)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Small Cell Lung Cancer/NET
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.12-21 - Outcomes with Immune Checkpoint Inhibitors (ICI) for Relapsed Small Cell Lung Cancer (SCLC) in a Swiss Cohort (ID 1026)

      10:15 - 18:15  |  Author(s): David Koenig

      • Abstract


      Chemotherapy for relapsed small-cell lung cancer (SCLC) has limited activity. Results from early clinical trials showed promising outcomes in a subset of patients with relapsed SCLC receiving ICI. Therefore, nivolumab +/- ipilimumab, pembrolizumab or atezolizumab have been used off-label in Switzerland.


      9 cancer centers in Switzerland contributed data to this retrospective cohort of patients who received off-label ICI for relapsed SCLC. Patient characteristics including age, smoking status, stage at diagnosis and previous treatments were collected. Outcomes of ICI were assessed by the local investigators using standard RECIST v1.1 criteria. Tumor tissues were assessed centrally for PD-L1 expression, tumor mutational burden and immune-related gene expression signatures.


      45 patients were included between November 2016 and January 2019. Median age was 63 years. 73% were males, 4% never smokers and 18% had a performance status (PS) ≥2. ICIs were given as second line treatment in 24 patients (53%). 24 patients (53%) received combination immunotherapy with ipiliumumab and nivolumab. 28 patients (62%) had undergone tumor irradiation (RT) prior to or during ICI. In the entire population, the overall response rate was 31%, while 49% had progressive disease as best response. Median progression-free survival was 2.5 months and median overall survival 6.5 months. There was no significant association between type of ICI (mono vs. combo) or prior RT vs. no RT with survival outcomes in a multivariate analysis. There were no new safety signals. One patient died of immune-related pneumonitis.


      This is the first report of “real-world” data on ICI in relapsed SCLC also including patients with poor PS. We confirm the efficacy and safety of ICI in relapsed SCLC as previously shown in clinical trials. No clinical prognostic marker could be identified. Results on the prognostic value of tissue-based biomarkers will be presented at the meeting.